Cargando…

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study

BACKGROUND: Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) compared to placebo in contrast to no reduction with dipeptidyl peptidase 4 (DPP4) inhibitors. However, there...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigiyama, Fumika, Kumashiro, Naoki, Fuchigami, Ayako, Hirose, Takahisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996551/ https://www.ncbi.nlm.nih.gov/pubmed/29895330 http://dx.doi.org/10.1186/s12933-018-0730-z

Ejemplares similares

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin’s Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes
por: Shigiyama, Fumika, et al.
Publicado: (2019)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
por: Hiruma, Shigenori, et al.
Publicado: (2021)

Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
por: Ando, Yasuyo, et al.
Publicado: (2021)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study
por: Kanazawa, Ken, et al.
Publicado: (2019)

A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan
por: Shigiyama, Fumika, et al.
Publicado: (2021)

CVR-MRICloud: An online processing tool for CO2-inhalation and resting-state cerebrovascular reactivity (CVR) MRI data
por: Liu, Peiying, et al.
Publicado: (2022)

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
por: Sorice, Gian Pio, et al.
Publicado: (2021)

Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies
por: Kang, So-Jin, et al.
Publicado: (2023)

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
por: Shigiyama, Fumika, et al.
Publicado: (2017)

DisCVR: Rapid viral diagnosis from high-throughput sequencing data
por: Maabar, Maha, et al.
Publicado: (2019)

Dependence of resting-state-based cerebrovascular reactivity (CVR) mapping on spatial resolution
por: Liu, Peiying, et al.
Publicado: (2023)

Improving the Breath-Holding CVR Measurement Using the Multiband Multi-Echo EPI Sequence
por: Cohen, Alexander D., et al.
Publicado: (2021)

ELITE: rationale and design of a longitudinal elite athlete, extreme cardiovascular phenotyping, prospective cohort study
por: van Hattum, Juliette C, et al.
Publicado: (2023)

Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study
por: Naidoo, Poobalan, et al.
Publicado: (2016)

Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design
por: Barreto, Joaquim, et al.
Publicado: (2023)

Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
por: Lee, Chi-Ho, et al.
Publicado: (2022)

Phylodynamics and evolutionary epidemiology of African swine fever p72-CVR genes in Eurasia and Africa
por: Alkhamis, Moh A., et al.
Publicado: (2018)

Utility of a Smartphone Based System (cvrPhone) to Predict Short-term Arrhythmia Susceptibility
por: Sohn, Kwanghyun, et al.
Publicado: (2019)

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
por: Cintra, Riobaldo M. R., et al.
Publicado: (2019)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus
por: Kazi, Mohsin, et al.
Publicado: (2020)

Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA)
por: Rodríguez-Artalejo, Fernando, et al.
Publicado: (2010)

The association between BOLD-based cerebrovascular reactivity (CVR) and end-tidal CO(2) in healthy subjects
por: Hou, Xirui, et al.
Publicado: (2019)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
por: Raji, Annaswamy, et al.
Publicado: (2020)

Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study
por: Parekh, Rulan S, et al.
Publicado: (2015)

The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population
por: Bhattacharjee, Rana, et al.
Publicado: (2023)

A Comparison of CVR Magnitude and Delay Assessed at 1.5 and 3T in Patients With Cerebral Small Vessel Disease
por: Stringer, Michael S., et al.
Publicado: (2021)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Prevalence of peripheral arterial disease in patients at non-high cardiovascular risk. Rationale and design of the PANDORA study
por: Cimminiello, Claudio, et al.
Publicado: (2010)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Evaluation of a standard provision versus an autonomy promotive exercise referral programme: rationale and study design
por: Jolly, Kate, et al.
Publicado: (2009)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study
por: Peasey, Anne, et al.
Publicado: (2006)

Cognitive Impairment in Diabetes: Rationale and Design Protocol of the Cog-ID Study
por: Koekkoek, Paula S, et al.
Publicado: (2015)

Rationale and Design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study
por: Moulson, Nathaniel, et al.
Publicado: (2023)

Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial
por: Pan, Yuesong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_03bd7rrfg3df1kfalg9m3i5dbk